- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00712296
Effectiveness of Chinese Herbal Therapy for Asthma
Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase II
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Asthma is a major public health problem worldwide, particularly in westernized societies and has continued to increase in prevalence over the past two decades. Inhaled corticosteroids have become the first-line treatment for persistent asthma even though side effects have been reported. New asthma medications, including leukotriene inhibitors and anti-IgE, have shown limited benefits. Patients have increasingly turned to complementary and alternative medicine (CAM) for treatment of their asthma, despite the uncertainty of its benefits due a lack of well-controlled scientific studies.
We have developed a Chinese herbal formula composed of 3 herbs called ASHMI. It has been previously shown in murine studies that ASHMI (a formula containing Ling Zhi, Ku Shen and Gan Cao) has therapeutic effects on the major pathogenic mechanisms of asthma-airway hyperreactivity, pulmonary inflammation, and airway remodeling, as well as a down-regulating of TH2 response. A subsequent study in 91 asthmatic patients in Weifang, China found ASHMI to be a safe and effective alternative to prednisone for treating asthma and exhibited a beneficial effect on TH1 and TH2 balance. Additionally, a Phase I study conducted in the United States showed good tolerability to ASHMI. Based on these preliminary studies, we hypothesize that ASHMI will be a safe medication in patients with asthma.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects ages 18 through 55 and otherwise in good health as determined by medical history and physical examination
- History of asthma documented by a physician for at least 6 months
- Females of childbearing potential must be sexually inactive or take effective birth control measures, as deemed appropriate by the investigator, for the duration of the study
- The subject agrees to participate in the study
- Subjects must have one of the following:
- one asthma-related unscheduled visit to an Emergency Department or clinic in the past 12 months
- One overnight hospitalization in the past 12 months
- Disturbed sleep more than twice in the past month
- Asthma symptoms ≥8 times in the past month
- use of a β2-agonist ≥8 times in the past month
- two short courses (3-7 days) of oral corticosteroids in the last 12 months
- FEV1 <80% predicted AND Use of inhaled corticosteroid (ICS) for at least 1 month prior to enrollment
Exclusion Criteria:
- Acute illness (such as cold, flu, etc.) within two weeks before the screening visit
- Any history of systemic disease that in the investigator's opinion would preclude the subject from participating in this study, including hepatitis virus infection
- History of chronic obstructive lung disease, emphysema, or other chronic respiratory condition
- Abnormal hepatic function (ALT/AST and bilirubin >1.25 x upper limit of normal)
- Abnormal bone marrow function (WBC <4 x 103/mm3; platelets <100 x 103/mm3; Hgb <11 g/dl)
- Abnormal renal function (BUN and creatinine >1.25 x upper limit of normal)
- Clinically significant abnormal electrocardiogram
- FEV1 <50% predicted
- Participation in another experimental therapy study within 30 days of this study
- History of alcohol or drug abuse
- Pregnant or lactating female subjects. Females of childbearing potential will need a negative serum pregnancy test at screening to be considered for this study
- Subjects receiving treatment with Omalizumab or immunotherapy for asthma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASHMI 4
ASHMI 4 capsules twice a day
|
4 capsules orally twice a day
|
Experimental: ASHMI 12
ASHMI 12 capsules twice a day
|
12 capsules orally twice a day
|
Placebo Comparator: Placebo
Placebo 6 capsules twice a day
|
Placebo 6 capsules twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose, Urea and Creatinine Phase I
Time Frame: 1 week after receiving active drug or placebo
|
Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL) and Creatinine(mg/dL) in subjects enrolled in Phase 1
|
1 week after receiving active drug or placebo
|
Sodium, Potassium, Chloride and CO2 Phase I
Time Frame: 1 week after receiving active drug or placebo
|
Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and CO2 (meq/L) in subjects enrolled in Phase 1
|
1 week after receiving active drug or placebo
|
Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase I
Time Frame: 1 week after receiving active drug and placebo
|
Summary of Laboratory data for Serum glutamic pyruvic transaminase and Serum glutamic oxaloacetic transaminase in subjects enrolled in Phase 1
|
1 week after receiving active drug and placebo
|
Laboratory Results for White Blood Cell, Hemoglobin and Platelet in Phase I
Time Frame: 1 week after receiving active drug and placebo
|
Summary of Laboratory data for White Blood Cell(cells*10^3/uL), Hemoglobin(cells*10^3/uL) and Platelet(cells*10^3/uL)in subjects enrolled in Phase 1
|
1 week after receiving active drug and placebo
|
Hemoglobin Laboratory Results in Phase I
Time Frame: 1 week
|
Summary of hemoglobin as Outcome measures included laboratory data for subjects enrolled in Phase 1
|
1 week
|
Laboratory Results for Glucose, Urea, Creatinine, Bilirubin Total and Bilirubin Direct Phase II Study
Time Frame: 28 weeks
|
Summary of Laboratory data for Glucose(mg/dL), Urea(mg/dL), Creatinine(mg/dL), Bilirubin Total(mg/dL) and Bilirubin Direct(mg/dL)in subjects in Phase II Limited to Measurements before discontinuation of ASHMI treatment |
28 weeks
|
Laboratory Results for Sodium,Potassium, Chloride and Bicarbonate in Phase II Study
Time Frame: 28 weeks
|
Summary of Laboratory data for Sodium(meq/L), Potassium(meq/L), Chloride(meq/L) and Bicarbonate(meq/L)in subjects in Phase II Limited to Measurements before discontinuation of ASHMI treatment |
28 weeks
|
Laboratory Results for Alkaline Phosphatase,Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase in Phase II Study
Time Frame: 28 weeks
|
Summary of Laboratory data for Alkaline phosphatase(IU/L),Serum glutamic pyruvic transaminase(IU/L)and Serum glutamic oxaloacetic transaminase(IU/L) in subjects in Phase II study Limited to Measurements before discontinuation of ASHMI treatment |
28 weeks
|
Laboratory Results for White Blood Cell Count and Platelet in Subjects in Phase II Study
Time Frame: 28 weeks
|
Summary of Laboratory data for White Blood Cell Count(cells*10^3/uL) and Platelet (cells*10^3/uL)in Phase II study Limited to Measurements before discontinuation of ASHMI treatment |
28 weeks
|
Laboratory Results for Hemoglobin in Subjects in Phase II Study
Time Frame: 28 weeks
|
Summary of Laboratory data for hemoglobin(g/dL)in subjects in Phase II study. Limited to Measurements before discontinuation of ASHMI treatment |
28 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Juan P Wisnivesky, MD, DrPH, Icahn School of Medicine at Mount Sinai
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 04-0206
- P01AT002647-02 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on ASHMI 4
-
Xiu-Min LiNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedNasal Decolonization of Staphylococcus AureusSweden
-
Janssen Research & Development, LLCCompleted
-
Maisonneuve-Rosemont HospitalCompleted
-
University of UtahNovartisWithdrawnEndometrial CancerUnited States
-
Jeffrey A. Cohen, MDJacobus PharmaceuticalTerminatedMuscle WeaknessUnited States
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
University Hospital, Strasbourg, FranceCompleted
-
DEKK-TEC, Inc.No longer availableAdvanced CancerUnited States
-
University of WashingtonRecruitingMultiple Sclerosis | FatigueUnited States